BAX326 (RIXUBIS): a novel recombinant factor IX for the control and prevention of bleeding episodes in adults and children with hemophilia B
| Autor: | Jerzy Windyga, Maria Helena Solano Trujillo, Andrea E. Hafeman |
|---|---|
| Rok vydání: | 2014 |
| Předmět: |
Pediatrics
medicine.medical_specialty Health-related quality of life Calidad de vida Reviews Hemophilia B law.invention Factor IX Cirugía law medicine Pharmacokinetics Seguridad Pediatric Health related quality of life Recombinant factor IX Bleeding episodes Prophylaxis business.industry Pediatría Hemofilia B Hematology Farmacocinética Recombinant DNA Surgery Safety business medicine.drug |
| Zdroj: | Repositorio Digital Institucional ReDi Fundación Universitaria de Ciencias de la Salud-FUCS instacron:Fundación Universitaria de Ciencias de la Salud-FUCS |
| ISSN: | 2040-6207 |
| Popis: | Hemophilia B management has improved considerably since the introduction of high-purity plasma-derived factor IX (pdFIX) products in the early 1990s. Recombinant FIX (rFIX) was introduced more recently and has potential safety advantages over the older blood-based products. Until recently, only one such product, nonacog alfa (BeneFIX®, Pfizer, Inc.), has been available. However, a new rFIX product, BAX326 (RIXUBIS, Baxter Healthcare Corp.), has now been approved by the US Food and Drug Administration. BAX326 undergoes rigorous virus elimination and purification steps during manufacture, and has low activated FIX activity, which confers low thrombogenic potential in humans. Preclinical studies showed promising pharmacokinetic and safety profiles, and these early findings have since been expanded in a series of prospective, multicenter, clinical studies. Foremost among these is a pivotal phase I/III study of BAX326 and its use in routine prophylaxis or on-demand treatment in patients aged 12–65 years with severe (FIX level |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|